Abstract:BACKGROUND: Achromobacter xylosoxidans is increasingly cultured in sputum from cystic fibrosis (CF) patients; nevertheless, there are few published data on the clinical impact of this infection or chronic colonisation.METHODS: Relying on DNA fingerprinting techniques we studied the prevalence of A. xylosoxidans in our CF population. In a retrospective case control study the clinical status of patients with at least 3 sputum cultures positive for A. xylosoxidans over at least 9 months, at the moment of the first positive culture and during the period of colonisation were compared to age (+/-1 year), gender and to Pseudomonas aeruginosa colonisation controlled CF patients who had never A. xylosoxidans positive sputum cultures.RESULTS: The prevalence of patients with at least one positive A. xylosoxidans culture was 17.9%. 5.3% of the patients fulfilled the criteria of our definition of colonisation. Colonised patients had a median age of 20 years (range 11-27 years) and a mean colonisation period of 1.5 (+/-0.9) years. At the moment of the first positive culture we found significantly lower Bhalla scores on HRCT scans of the lungs (11+/-3 versus 16+/-3, p<0.002), lower Brasfield chest X-ray scores (14+/-3 versus 18+/-3, p<0.019), lower FVC values (70%+/-22 versus 94%+/-12, p<0.017) and lower FEV(1) values (55%+/-32 versus 78%+/-23, p=0.123), although the latter did not reach significance. There was no significant difference in body mass index (BMI) (18.7+/-3 kg/m2 versus 19.6+/-3 kg/m2, p=0.8). Over the study period A. xylosoxidans-colonised patients did have more need for intravenous antibiotic treatment courses (19 versus 5, p<0.001); nevertheless, there was no significant difference in lung function decline over the study period (FVC: -6.25+/-12.34% versus -5.62+/-8.30%, p 0.77, FEV1: -5.62+/-8.30% versus -1.87+/-11.58%, p<0.47).CONCLUSIONS: The prevalence of A. xylosoxidans infection or colonisation is probably underestimated. Colonised patients are mostly older, with more pronounced lung damage and lower lung function values. Although there was more need for intravenous antibiotic treatment courses, no faster decline in lung function was observed in A. xylosoxidans positive patients.

Direct Detection of Exophiala and Scedosporium Species in Sputa of Patients with Cystic Fibrosis

Reverse Line Blot Hybridisation Screening of Pseudallescheria/Scedosporium Species in Patients with Cystic Fibrosis

Challenges in Laboratory Detection of Fungal Pathogens in the Airways of Cystic Fibrosis Patients

Detection of pathogenic bacteria and biomarkers in lung specimens from cystic fibrosis patients

Ability of device to collect bacteria from cough aerosols generated by adults with cystic fibrosis

Detection of Specific IgE against Molds Involved in Allergic Bronchopulmonary Mycoses in Patients with Cystic Fibrosis

H. influenzae and S. aureus detection through breath analysis in PCD patients

The fungal diversity in the lungs of children with cystic fibrosis captured by sputum-induction and bronchoalveolar lavage

Early detection of Pseudomonas aeruginosa – comparison of conventional versus molecular (PCR) detection directly from adult patients with cystic fibrosis (CF)

Methods for Extraction and Detection of Pf Bacteriophage DNA from the Sputum of Patients with Cystic Fibrosis

P174 High Aerosol Production of Potentially Infectious Cough Aerosols in People with Cystic Fibrosis During Coughing

Improved culture detection of Staphylococcus aureus from sputum of patients with cystic fibrosis (CF)

Detection of cytokines in nasal lavage samples of patients with cystic fibrosis: comparison of two different cytokine detection assays

The Convoluted Process of Diagnosing Pulmonary Mycosis Caused by Exophiala Dermatitidis: a Case Report.

Detection of relationship between pathogens of acute exacerbation of chronic obstructive pulmonary disease and comprehensive evaluation classification

An invisible threat? Aspergillus positive cultures and co-infecting bacteria in airway samples

Monitoring cystic fibrosis airway infections with Pseudomonas aeruginosa with anti-OprF serum antibodies

Achromobacter xylosoxidans in cystic fibrosis: Prevalence and clinical relevance

Evaluation of CHROMagarTM B. cepacia agar for the detection of Burkholderia cepacia complex species from sputum samples of patients with cystic fibrosis

Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients

Development of a Diagnostic PCR Assay That Targets a Heat-Shock Protein Gene (groes) for Detection of Pseudomonas Spp. in Cystic Fibrosis Patients.